Modality
mAb
MOA
DLL3 ADC
Target
CD19
Pathway
Lipid Met
GAHCCBCC
Development Pipeline
Preclinical
~Nov 2009
→ ~Feb 2011
Phase 1
~May 2011
→ ~Aug 2012
Phase 2
~Nov 2012
→ ~Feb 2014
Phase 3
~May 2014
→ ~Aug 2015
NDA/BLA
~Nov 2015
→ ~Feb 2017
Approved
May 2017
→ Mar 2031
ApprovedCurrent
NCT06992518
2,333 pts·BCC
2017-05→TBD·Not yet recruiting
NCT08196568
554 pts·HCC
2025-06→2027-07·Terminated
NCT08345133
2,287 pts·HCC
2024-10→2031-03·Not yet recruiting
+1 more trial
5,279 total pts2 indications
CompletedCurrentUpcoming
Catalysts (3)
2025-12-243mo agoPh3 Readout· BCC
2027-07-091.3y awayPh3 Readout· HCC
2031-03-014.9y awayPh3 Readout· HCC
Trial Timeline
Q2Q3Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2
Approved
Not yet…
Approved
Recruit…
Approved
Not yet…
Approved
Termina…
Catalysts
Ph3 Readout
2025-12-24 · 3mo ago
BCC
Ph3 Readout
2027-07-09 · 1.3y away
HCC
Ph3 Readout
2031-03-01 · 4.9y away
HCC
RecruitingTerminatedNot yet recruiting|StartCompletionToday
Trials (4)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06992518 | Approved | BCC | Not yet recr... | 2333 | CfB |
| NCT08196568 | Approved | HCC | Terminated | 554 | PASI75 |
| NCT08345133 | Approved | HCC | Not yet recr... | 2287 | UPDRS |
| NCT03662120 | Approved | BCC | Recruiting | 105 | 6MWD |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-8662 | Pfizer | NDA/BLA | CD19 | |
| NVS-4076 | Novartis | Preclinical | TROP-2 | |
| NVS-6974 | Novartis | Preclinical | CD19 | |
| Voxarasimod | Merck & Co | Phase 1/2 | CD19 | |
| Rimamavacamten | Merck & Co | Phase 1 | PI3Kα | |
| AMG-9654 | Amgen | Phase 2 | GPRC5D | |
| Tirarelsin | TG Therapeutics | NDA/BLA | CD19 | |
| Tixatapinarof | Arvinas | Phase 1/2 | CDK2 | |
| VYG-2926 | Voyager | NDA/BLA | CD19 | |
| SDG-1247 | Schrodinger | Phase 1 | CD19 |